Cap Insulin Prices Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Cap Insulin Prices Act
This bill reduces cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.
Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $25 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2024.
The bill caps cost-sharing under the Medicare prescription drug benefit for a month's supply insulin products at $25 beginning in 2024. The current cap on insulin products under Medicare is $35 per month.
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 146: Cap Insulin Prices Act. 118th Congress. Open America. https://openamerica.io/bill/118-S-146/
"S. 146: Cap Insulin Prices Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-146/.
S. 146, 118th Cong. (2026), https://openamerica.io/bill/118-S-146/.
[S. 146: Cap Insulin Prices Act](https://openamerica.io/bill/118-S-146/)